Rate My Professor Oskar Hansson

Hansson's research specializes in the early phases of Alzheimer’s and Parkinson’s diseases, focusing on biomarkers and diagnostic algorithms for early diagnosis, as well as the consequences of brain pathologies on cognitive, neurologic, and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders. He heads the prospective and longitudinal Swedish BioFINDER studies (www.biofinder.se). He has authored over 400 original peer-reviewed publications, including key works such as “Tau PET imaging can with high accuracy distinguish Alzheimer’s from all other neurodegenerative diseases” (JAMA, 2018), “Tau PET imaging predicts cognitive decline in cognitively normal individuals” (Nature Medicine, 2022), “Tau PET imaging detects different subtypes of Alzheimer’s” (Nature Medicine, 2021), and multiple studies on blood-based biomarkers for early detection of Alzheimer’s disease (Nature Medicine 2020, JAMA 2020, Nature Aging 2021, Nature Medicine 2021, Nature Medicine 2022, Nature Medicine 2024, JAMA 2024). His impact is recognized through major awards, including the Torsten Söderberg Professorship in Medicine (2024), De Leon Prize in Neuroimaging (2023), Elsa and Alfred Eriksson Award (2023), European Research Council Advanced Grant (2023), and NIH/NIA R01 grant as principal investigator (2023).